D.E. Shaw & Co
KRTX

D.E. Shaw & Co’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

D.E. Shaw & Co’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-48,800
Closed -$15.4M – 4866
2023
Q4 		$15.4M Buy
48,800
+3,600
+8% +$700K 0.01% 1088
2023
Q3 		$7.64M Buy
45,200
+4,100
+10% +$771K 0.01% 1475
2023
Q2 		$8.91M Buy
41,100
+20,700
+101% +$4.43M 0.01% 1433
2023
Q1 		$3.71M Buy
20,400
+10,400
+104% +$1.99M ﹤0.01% 2201
2022
Q4 		$1.97M Hold
10,000
– – ﹤0.01% 2954
2022
Q3 		$2.25M Buy
+10,000
New +$2.02M ﹤0.01% 2892

Other funds holding KRTX

IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
S
Sachetta Lynnfield, Massachusetts $206M AUM 26.19% 1-Year Est. Return

D.E. Shaw & Co's KRTX Position: Q1 2024 in Review

D.E. Shaw & Co sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q1 2024, closing a stake of 19,131 shares — an estimated $6.06M sold.

D.E. Shaw & Co first reported a position in KRTX in Q4 2019 and held it in 11 quarters. The position peaked at $71.6M in Q3 2022. 2 funds tracked by Wall St. Rank hold KRTX as of Q1 2024.

  • D.E. Shaw & Co reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q1 2024 after selling out during the quarter.
  • D.E. Shaw & Co sold 19,131 Karuna Therapeutics, Inc. Common Stock shares in Q1 2024, an estimated $6.06M.
  • D.E. Shaw & Co first reported a position in Karuna Therapeutics, Inc. Common Stock in Q4 2019 and held it in 11 quarters.
  • D.E. Shaw & Co's Karuna Therapeutics, Inc. Common Stock position peaked at $71.6M in Q3 2022.
  • 2 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q1 2024.

Based on D.E. Shaw & Co's 13F filing for Q1 2024, filed 15 May 2024.